GlassScriptPhysician profile
Wallace F Burroughs
NPI 1952306029
$5,947.94
in general payments reported to CMS, 2019-2025
32 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $849 · 2020: $588 · 2021: $1,016 · 2022: $939 · 2023: $1,371 · 2024: $1,063 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,523 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,523.24 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,444.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $924.02 | 2019-2024 | Repatha, Otezla, Prolia |
| Lilly USA, LLC | $658.83 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $484.33 | 2021-2025 | Vraylar, Qulipta |
| Pfizer INC. | $399.23 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $256.07 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.14 | 2020-2024 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $173.41 | 2019-2024 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $171.96 | 2020-2024 | Shingrix, Arexvy, Boostrix |
| Bayer Healthcare Pharmaceuticals INC. | $156.11 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $150.94 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $138.69 | 2019-2024 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.05 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $85.52 | 2019-2024 | Gardasil, Gardasil 9, Vaqta |
| Dynavax Technologies Corporation | $70.29 | 2024 | Heplisav-B |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $58.66 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $54.20 | 2023-2024 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $50.59 | 2020-2021 | |
| Amarin Pharma, INC. | $48.12 | 2020 | |
| Jazz Pharmaceuticals INC. | $45.66 | 2020-2021 | |
| Abbott Laboratories | $38.24 | 2022-2023 | Freestyle Libre 3 |
| Exact Sciences Corporation | $36.10 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $31.28 | 2024 | Veozah |
| Currax Pharmaceuticals LLC | $26.54 | 2021-2022 | |
| Daiichi Sankyo INC. | $25.63 | 2023 | Injectafer |
| Nevro Corp. | $23.63 | 2024 | Senza |
| Biohaven Pharmaceutical Holding Company LTD. | $22.86 | 2022 | |
| Philips North America LLC | $21.91 | 2024 | (Ck7) Extended Holter |
| Hologic Sales and Service, LLC | $18.64 | 2024 | Aptima |
| Allergan, INC. | $13.90 | 2020 | |
| Sanofi Pasteur INC. | $12.29 | 2019 | |
| Medtronic Minimed, INC. | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wallace Burroughs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.